Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.68 |
| ▸ | TP53 | P04637 | 12/20 | 0.68 |
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21623379 | 1.00 | MAPT (0.68) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL21623153 | 1.00 | MAPT (0.68) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL21623255 | 0.95 | MAPT (0.73) | MAPTTP53LMNATSHRPOLB | |
| SCHEMBL15076341 | 0.94 | MAPT (0.62) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL21623565 | 0.94 | MAPT (0.62) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL21623126 | 0.94 | MAPT (0.62) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL17085002 | 0.91 | MAPT (0.81) | MAPTTP53LMNAPOLB | |
| SCHEMBL21623359 | 0.90 | MAPT (0.56) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL21623077 | 0.90 | MAPT (0.56) | MAPTTP53LMNACYP1A2CYP3A4 | |
| SCHEMBL15076479 | 0.90 | TP53 (0.61) | MAPTTP53LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| CN-112912368-A | Inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3823957-A1 | INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020016427-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016427-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, HDGF | MAPT 3587/4885TP53 979/4885LMNA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.